Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck

International Journal of Clinical Oncology

Volumn 9, Issue 2, 2004, Pages 107-112

  Fujii, Masato ^a   Tsukuda, Mamoru ^b   Satake, Bunsuke ^c   Kubota, Akira ^d   Kida, Akinori ^e   Kohno, Naoyuki ^f   Okami, Kenji ^g   Inuyama, Yukio ^h  

^a KEIO UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Gunma Cancer Center   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TOKAI UNIVERSITY   (Japan)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Concurrent chemoradiotherapy; Docetaxel; Head and neck cancer; Phase I trial; Phase II trial

Indexed keywords

DOCETAXEL;

ADULT; ADVERSE DRUG REACTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG RESPONSE; DRUG TOXICITY; DYSGEUSIA; DYSPHAGIA; EDEMA; FATIGUE; FEMALE; FEVER; FLATULENCE; FOLLOW UP; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEMOGLOBINEMIA; HEMOGLOBINOPATHY; HOARSENESS; HUMAN; HYPOCALCEMIA; HYPOGLYCEMIA; INFECTION; JAPAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RASH; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TAXOIDS; TREATMENT OUTCOME;

EID: 2442452619     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-003-0375-z     Document Type: Article

References (30)

1. Vokes EE, Weichselbaum RR, Lippman SM, et al. (1993) Head and neck cancer. N Engl J Med 328:184-194
2. Forastiere AA, Berkey B, Maor M, et al. (2001) Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc Am Soc Clin Oncol 20:2a (abstr. 4)
3. Vokes EE, Weichselbaum RR (1990) Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8:911-934
4. Pignon JP, Bourhis J, Domenge C, et al. (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group, Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955
5. Dreyfuss AL, Clark JR, Norris CM, et al. (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14:1672-1678
6. Ringel I, Horwitz SB (1991) Studies with RP-56976 (Taxotere): a semi-synthetic analogue of Taxol. J Natl Cancer Inst 83:288-291
7. Choy H, Rodriguez F, Wilcox B, et al. (1992) Radiation sensitizing effects of taxotere. Proc Am Assoc Cancer Res 33:500
8. Chaffey JT, Hellman S (1971) Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res 31:1513-1616
9. Mauer AM, Masters GA, Haraf DJ, et al. (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159-164
10. Koukourakis MI, Kourousis C, Kamilaki M, et al. (1998) Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34:838-844
11. Rooney M, Kish J, Jacobs J, et al. (1985) Improved complete response rate and survival in advanced head and neck cancer after three course induction therapy with 120-h 5-FU infusion and cisplatin. Cancer 55:1123-1128
12. Paccagnella A, Orlando A, Marchiori C, et al. (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272
13. Head and Neck Contracts Program (1987) Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of the Head and Neck Contracts Program. Cancer 60:301-311
14. Schuller DE, Metch B, Stein DW, et al. (1988) Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 98:1205-1211
15. Munro AJ (1995) An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83-91
16. Adelstein DJ, Sharan VM, Earle AS, et al. (1990) Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer. Am J Clin Oncol 13:440-447
17. Taylor SG IV, Murthy AK, Vannetzel JM, et al. (1994) Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12:385-395
18. Colevas AD, Norris CM, Tishler RB, et al. (1999) Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17:3505-3511
19. Hennequin C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 15:1842-1850
20. Tishler RB, Schiff PB, Geard CR, et al. (1992) Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617
21. Creane M, Seymour CB, Colucci S, et al. (1999) Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol 75:731-737
22. Catimel G, Verweij J, Mattijssen V, et al. (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:533-537
23. Hainsworth JD, Burris HA, Erland JB, et al. (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168
24. Hilkens PH, Verweij J, Vecht CJ, et al. (1997) Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 8:187-190
25. Hesse K, Heinrich B, Zimmermann F, et al. (2000) Combined radiochemotherapy with docetaxel in patients with unresectabIe locally advanced head and neck tumors. Strahlenther Onkol 176:67-72
26. Horiot JC, Le Fur R, Nguyen T, et al. (1992) Hyperfractionation versus conventional fraction in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231-241
27. Wanebo H, Chougule P, Ready N, et al. (2001) Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol 8:644-650
28. Mucke R, Blynow M, Ziegler PG, et al. (1999) Simultaneous radiochemotherapy with carboplatin in patients with inoperable advanced stage III and IV head and neck tumors. Strahlenther Onkol 175:213-217
29. Marmiroli L, Nardone L, Salvi G, et al. (1998) Chemoradiotherapy with carboplatin in continuous infusion in the locoregional control of advanced head and neck cancer. Rays 23:549-554
30. Lavertu P, Adelstein DJ, Saxton JP, et al. (1999) Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience. Arch Otolaryngol Head Neck Surg 125:142-148